[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Ramsha Iqbal Maqsood M Yaqub Husseyin O Bektas Daniela-Elena Oprea-Lager Elisabeth G E de Vries Andor W J M Glaudemans Philippe Aftimos Géraldine Gebhart Andrew P Beelen Robert C Schuit Albert D Windhorst Ronald Boellaard Catharina Willemien Menke-van der Houven van Oordt

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the (reversible) effect of therapy and continued mode of action of SERDs.

Keyphrases

pet ct
positron emission tomography
poor prognosis
high resolution
estrogen receptor
computed tomography
pet imaging
breast cancer cells
stem cells
bone marrow
replacement therapy
young adults
binding protein
fluorescence imaging